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Abstract
The telomerase reverse transcriptase synthesizes new telomeres onto chromosome ends by copying from a short template
within its integral RNA component. During telomere synthesis, telomerase adds multiple short DNA repeats successively, a
property known as repeat addition processivity. However, the consequences of defects in processivity on telomere length
maintenance are not fully known. Germline mutations in telomerase cause haploinsufficiency in syndromes of telomere
shortening, which most commonly manifest in the age-related disease idiopathic pulmonary fibrosis. We identified two
pulmonary fibrosis families that share two non-synonymous substitutions in the catalytic domain of the telomerase reverse
transcriptase gene hTERT: V791I and V867M. The two variants fell on the same hTERT allele and were associated with
telomere shortening. Genealogy suggested that the pedigrees shared a single ancestor from the nineteenth century, and
genetic studies confirmed the two families had a common founder. Functional studies indicated that, although the double
mutant did not dramatically affect first repeat addition, hTERT V791I-V867M showed severe defects in telomere repeat
addition processivity in vitro. Our data identify an ancestral mutation in telomerase with a novel loss-of-function mechanism.
They indicate that telomere repeat addition processivity is a critical determinant of telomere length and telomere-mediated
disease.
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Introduction
Telomerase is a specialized DNA polymerase that synthesizes
new telomere repeats onto chromosome ends [1,2]. Telomerase
has two essential conserved components, a catalytic reverse
transcriptase, hTERT, and an RNA component, hTR [3,4].
The RNA component of telomerase contains a template sequence
for the addition of new telomere repeats [5]. In order to synthesize
long telomere tracts, hTERT copies from the RNA template once,
translocates, and then iteratively adds successive repeats [6]. This
property is known as telomere repeat addition processivity [7].
Functional domains within hTR and hTERT, as well as
telomerase-extrinsic factors, have been implicated in repeat
addition processivity [8–10]. However, whether repeat addition
processivity is critical for telomere length maintenance in vivo is not
fully known.
Germline mutations in the essential telomerase components
hTERT and hTR lead to a clinical spectrum of syndromes of
telomere shortening (reviewed in [11]). Affected individuals suffer
from degenerative organ failure in the bone marrow, lung and
liver. In adulthood, syndromes of telomere shortening most
commonly manifest as progressive and irreversible scarring of
the lung in an age-related disorder known as idiopathic pulmonary
fibrosis (IPF) [11]. Mutations in hTERT or hTR underlie the
inheritance in 8–15% of familial forms of pulmonary fibrosis and
1–3% of sporadic cases [12–15]. This mutation frequency along
with the common prevalence of IPF make pulmonary disease the
most common manifestation of germline defects in telomerase
[11]. In severe forms, syndromes of telomere shortening are
clinically recognized in the premature aging syndrome dyskeratosis
congenita where aplastic anemia is the most common cause of
mortality and where there is an increased incidence of acute
myeloid leukemia (AML) [16,17]. AML, both de novo, and in the
setting of myelodysplasia, has also been reported as a first
manifestation of germline mutant telomerase genes [18,19]. A
subset of pulmonary fibrosis patients and families with short
telomeres suffer complications from aplastic anemia and crypto-
genic liver cirrhosis [12,13,20,21]. Insights into telomerase
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therefore become intimately connected with the pathophysiology
of several age-related disorders.
Heterozygous mutations in hTERT and hTR cause telomere
shortening through haploinsufficiency [20–23]. Previously identi-
fied mutations in telomerase have been shown to cause loss-of-
function due to defects in hTR stability, essential catalytic
function, and ribonucleoprotein assembly, but not repeat addition
processivity [13,20,22,24,25]. We identified two families with
familial pulmonary fibrosis where each of the affected index cases
carried two heterozygous variants that predicted non-synonymous
amino acid substitutions in the reverse transcriptase domain of
hTERT. We show that these two families share a common
founder, identifying an ancestral mutation in telomerase. Although
the double heterozygote hTERT did not drastically affect
telomerase’s capacity to add nucleotides within a single repeat, it
had severe defects in repeat addition processivity and was
associated with telomere shortening. Our data indicate that
inherited defects in telomerase processivity may be sufficient to
contribute to telomere shortening and to a familial telomere-
mediated syndrome.
Results
Non-synonymous variants in the reverse-transcriptase
domain of hTERT segregate with the pulmonary fibrosis
phenotype
In a screen of 75 familial pulmonary fibrosis probands for
telomerase mutations, we identified a proband from a family
designated number 13 who carried two single nucleotide variants
in hTERT. The first was a c.2371GRA transition in exon 7, and
the second was c.2599GRA transition in exon 10 (Figure 1A, 1B).
These predicted two non-synonymous substitutions in the reverse
transcriptase domain: V791I and V867M, respectively (Figure 1C).
The single nucleotide variants were absent in 200 ethnically
matched controls, as well as in a multi-ethnic control panel
examining the hTERT gene sequence [23]. To determine whether
these nucleotide substitutions were on the same allele (i.e. in cis)
and whether they were associated with the pulmonary fibrosis
phenotype, we sequenced genomic DNA from affected family
members and examined the segregation. hTERT V791I and
V867M were always present together (11 of 11 individuals across 3
generations) suggesting that they were on the same hTERT
haplotype (Figure 2). The hTERT variants predicting V791I and
V867M segregated with the pulmonary fibrosis diagnosis across
four generations in all the individuals we examined [n=7, 5
directly sequenced, 1 obligate carrier (13.II.5) and 1 probable
carrier (13.I.1), Figure 2]. The log of the odds ratio (LOD) score of
the mutant hTERT allele segregating with the pulmonary fibrosis
was significant at 3.3. The segregation of the mutations with the
disease phenotype indicated that this double mutant hTERT was
likely disease causing.
Two pulmonary fibrosis families share common ancestry
In an independent screen of 24 pulmonary fibrosis families, we
identified a second kindred, designated family 143, whose proband
carried the identical substitutions in hTERT. In this family,
hTERT V791I and hTERT V867M also co-segregated with the
pulmonary fibrosis phenotype (Figure 2). Since the two variants
were in cis and were rare, we reasoned that Families 13 and 143
may have a single common ancestor. To address this, we carefully
queried the genealogy. Independently, members of the two
families reported lineage to an individual of the same surname
who was born in 1808 in the United States. According to public
census records, this ancestor had grandparents who emigrated in
the eighteenth century from the British Isles. The genealogy
suggested that Families 13 and 143 may be related and that the
putative mutation(s) have been present for at least 6 generations,
possibly with ancestry as far back as the early nineteenth century.
To determine whether Families 13 and 143 shared a common
founder, we genotyped polymorphic microsatellite and minisatel-
lite sequences that flank as well as fall within the hTERT gene
(Figure S1A, S1B). In all the individuals who carried the hTERT
substitutions at 791 and 867 positions, we identified a shared
haplotype block which was both within and flanked hTERT
(Figure S1A, S1B). These data, together with the family histories,
indicated that Families 13 and 143 shared a common ancestor
who carried the double mutant hTERT allele.
hTERT 791I-867M causes defects in repeat addition
processivity in vitro
To determine the functional significance of the hTERT 791 and
867 variants, we first examined the evolutionary conservation of
the hTERT V791 and V867 residues. hTERT V791 fell within
the insertion in finger domain (IFD) between the A and B motifs of
the reverse transcriptase domain [10,26], a telomerase specific
motif (Figure 1B, 1C). hTERT V867 fell within the universal
reverse transcriptase motif C, and was adjacent to the invariant
aspartic acid residues which are essential for the catalytic function
of telomerase and other reverse transcriptases [4] (Figure 1B, 1C).
The sequence alignment from representative species showed that
these two residues are generally conserved as hydrophobic amino
acids in most organisms, and are therefore potentially important
for telomerase function.
To directly examine whether the variant hTERT affects
telomerase activity, we reconstituted the mutant telomerase and
measured enzyme activity in vitro. At standard assay conditions of
1 mM nucleotide concentrations [8,12,13,20,27], the 791I alone
did not have obvious defects in activity or processivity (Figure 3A,
lane 3). A minor inter-repeat pause was present for 867M; this has
been previously suggested to be due to nucleotide affinity defects
Author Summary
Mutations in the essential telomerase components cause a
spectrum of diseases mediated by short telomeres. Most
frequently, these disorders manifest in the lung in an age-
related disease: idiopathic pulmonary fibrosis. Telomerase
synthesizes telomere repeats using a specialized reverse
transcriptase, hTERT, that copies from a short template
within its intrinsic RNA. In order to add long telomere
tracts, telomerase adds a single repeat followed by
additional repeats successively. This property, known as
repeat addition processivity, is unique to the telomerase
polymerase. We identified two families that shared two
unique variants in the catalytic domain of hTERT: V791I
and V867M. The variants co-segregated, indicating they
are on the same allele, and were associated with short
telomeres. Family history suggested the two families may
have a single ancestor, and genetic studies confirmed they
had a common founder. Telomerase reconstitution indi-
cated that, although the double mutant did not signifi-
cantly affect telomerase’s ability to add a single telomere
repeat, hTERT 791I-867M had severe defects in repeat
addition processivity. Our data identify an ancestral
mutation in telomerase; this mutation possesses a unique
loss-of-function mechanism. Defects in telomere addition
processivity are important determinants of telomere
length maintenance and of telomere-associated disease.
Telomerase Ancestral Mutation Impairs Processivity
PLoS Genetics | www.plosgenetics.org 2 March 2011 | Volume 7 | Issue 3 | e1001352[28] (Figure 3A, lane 4). This pause was also present in the 791I-
867M double mutant (Figure 3A, lane 5). However, the overall
activity and processivity of 867M and 791I-867M were not
affected (Figure 3A, lanes 4 and 5). For comparison, we measured
the activity of a known hTERT mutation L55Q previously
identified in a family with pulmonary fibrosis [13]. This mutant
showed a significant decrease in overall activity (Figure 3A, lane 2).
Since the segregation and the genetic evidence supported the 791I-
867M being a pathogenic allele, we assayed its function at
nucleotide concentrations that are closer to the estimated Km for
telomerase [29,30]. The lower concentrations also more closely
mimic estimates of intra-nuclear nucleotide concentrations
(10 mM) [31–33]. Under these conditions, there was little effect
on the synthesis of the first repeat compared with wildtype
telomerase (Figure 3A–3D). We next measured repeat addition
processivity. Notably, hTERT 867M and the double mutant
hTERT had significant decreases in repeat addition processivity
(Figure 3A and 3E). The decreased repeat addition processivity
was not seen for the 55Q and 791I alleles (Figure 3A and 3E). This
decrease was evident by the lower intensity of high molecular
weight repeat products relative to the first product (Figure 3A, lane
6 compared with lanes 9 and 10). For example, by the fourth
Figure 1. Position and conservation of non-synonymous variants in hTERT shared by pulmonary fibrosis families 13 and 143
probands. A,B. Chromatograms of single nucleotide variants predict non-synonymous amino acid substitutions. The first was a c.2371GRA
transition in exon 7 (A), and the second was c.2599GRA transition in exon 10 (B). C. Panel shows conserved hTERT motifs shared with other TERTs.
The non-synonymous amino acid variant residues are indicated within the reverse transcriptase domain. hTERT V791 falls in the IFD domain between
the A and B motifs, and hTERT V867 is adjacent to the invariant motif C aspartic acid residues which are essential for reverse transcriptase function
and are indicated by *. Alignment of TERT sequence across 14 species indicates that both V791 and V867 fall within conserved motifs.
doi:10.1371/journal.pgen.1001352.g001
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10-fold reduction in telomere product compared with wildtype
telomerase (Figure 3E). The decrease in processivity was
independent of the hTERT epitope tag used in affinity purifi-
cation, as we saw the same degree of impairment for 867M and
791I-867M whether a C-terminal HA or N-terminal FLAG
epitope was used (not shown). To exclude the possibility that the
double mutant hTERT may have dominant negative effects, we
performed mixing studies of wildtype and 791I-867M and found
no additional decreases in activity or processivity (not shown).
These data indicated that although hTERT 791I and 867M co-
segregate with the disease phenotype, the 867M mutation appears
to be the pathogenic variant and predominantly affects telomere
repeat addition processivity in vitro.
Mutant TERT is associated with short telomere length
Telomerase haploinsufficiency causes telomere shortening and
the severity of the consequent phenotypes correlates with the
telomere length [20,34]. To examine if the mutant telomerase is
associated with telomere shortening, we measured telomere length
in family members using combined flow cytometry and fluores-
cence in situ hybridization (flow-FISH) [12,13]. In all cases,
mutation carriers had lymphocyte telomere lengths below the 10
th
percentile of a normal distribution compared with age-matched
controls (Figure 4). In 6 of 9 mutation carriers, the telomere length
fell below the 1
st percentile, a range that is highly specific for the
presence of a germline telomere maintenance defect [12,13,35]
(Figure 4, P,0.001, paired t-test). Therefore the mutant hTERT is
associated with telomere shortening in mutation carriers.
A spectrum of telomere-mediated disease is associated
with ancestral TERT mutation
Syndromes of telomere shortening manifest as degenerative
disease in the lung, liver and bone marrow, and a subset of
pulmonary fibrosis families falls on this spectrum [11,13]. To
examine whether the mutant TERT leads to the full spectrum of
telomere-mediated disease, we characterized the clinical pheno-
types in families 13 and 143. Of the 18 genetically affected
individuals in the two pedigrees, 11 had pulmonary disease. In the
majority of cases (7 of 11, 64%), the interstitial lung disease met
the criteria for usual interstitial pneumonia/IPF (Figure 5A, 5B
and Table S1). In affected individuals, the onset of disease was in
adulthood with a mean age of 56 (range 32–67). There was very
subtle genetic anticipation for the age at death across the
generations we could examine (e.g. age 61 and mean age 56 for
generations I and II respectively in family 13, Table S1). Two
individuals at the age of 50 and 51 reported chronic liver function
abnormalities that were unexplained after a thorough work-up.
We identified subclinical cytopenias in one individual (age 50), and
one individual was diagnosed with AML at age 67 and
subsequently died from complications of interstitial lung disease
(Table S1). We clinically examined the probands and their
relatives for the typical mucocutaneous features of dyskeratosis
congenita but did not identify any signs of skin hyperpigmentation,
nail dystrophy or oral leukoplakia. Therefore the telomerase defect
we identified in families 13 and 143 appears to primarily cause
adult-onset phenotypes. These phenotypes are clinically most
prominent in the lung, but features of the full spectrum of a
telomere syndrome manifest at lower frequency including
subclinical cytopenias, liver function abnormalities and AML.
Unaffected siblings of mutation carriers have short
telomeres
Telomere length is a heritable trait and parental telomere length
determines offspring telomere length even when telomerase is
wildtype [34,36,37]. In a large dyskeratosis congenita family,
siblings of mutation carriers were shown to have short telomeres;
however telomere-related phenotypes in these individuals have not
been previously reported [38]. Since the hTERT 791I-867M
mutation was associated with short telomeres, we examined
whether their non-mutation carrier relatives may also have short
telomeres. In 4 individuals we examined, the lymphocyte telomere
length was below the 10
th percentile compared with age-matched
controls, and in two individuals, the telomere length fell at or
below the 1
st percentile (Figure 4, P=0.039, paired t-test). To
determine whether short telomeres may be a risk factor for
developing telomere-mediated disease, we examined the clinical
phenotypes of the individuals who did not carry the hTERT 791I-
867M allele but who had short telomeres. We identified one
patient who presented to our clinic with shortness of breath at the
Figure 2. Four generation pedigrees of pulmonary fibrosis probands from Families 13 and 143 of the Vanderbilt Registry. Mutation
and affected status are indicated by symbols shown in the key and individuals in whom DNA was available are noted by the pedigree number in bold
text. In both families, the hTERT 791I and 867 M variants co-segregate, consistent with the fact that these heterozygous substitutions are on the same
allele in cis. hTERT 791I-867M also segregates with the pulmonary fibrosis phenotype in all the individuals in whom DNA was available. The symbols
are identified in the key, and completely filled symbols indicate clinically affected individuals who carry the double mutant TERT.
doi:10.1371/journal.pgen.1001352.g002
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PLoS Genetics | www.plosgenetics.org 4 March 2011 | Volume 7 | Issue 3 | e1001352Figure 3. The ancestral mutant telomerase affects repeat addition processivity in vitro. A. Telomerase activity assay of non-synonymous
hTERT variants identified in family 13 and 143 probands. L55Q was previously identified in a pulmonary fibrosis family and known to compromise
catalysis. Telomerase activity assay at high nucleotide (1 mM) concentrations on the left shows no defects in catalytic activity or processivity for
hTERT V791I and V867M or the double mutant. At lower nucleotide concentration (10 mM), hTERT 867M and hTERT V791I-V867M both show defects
in repeat addition processivity as evidenced by the decreased intensity of the high molecular weight products relative to the first repeat. Low
exposure image of the internal loading control is shown below. B. Low exposure image of the gel shown in (A) is shown to visualize the +1, +2, and
+3 nucleotide bands clearly. C. SDS-PAGE of
35S labeled hTERT used in (A) to monitor the expression of in vitro synthesized hTERTs. D. Quantitation of
Telomerase Ancestral Mutation Impairs Processivity
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cigarette use (greater than 50 pack-years). The patient’s CAT scan
showed a mixed picture of interstitial lung disease with ground
glass infiltrates and emphysema (Figure 5C, 5D), and lung biopsy
confirmed the presence of interstitial fibrosis on the background of
bronchiolitis. Although cigarette smoke has been shown to be
associated with short telomeres and is known to contribute to the
risk of both emphysema and pulmonary fibrosis [39], it is
intriguing to consider the possibility that parental telomere length
may have contributed to the telomere shortening in this individual
and to his risk of lung disease.
Discussion
Repeat addition processivity is a unique biochemical attribute of
the telomerase reverse transcriptase, and here we show it may be
critical for telomere maintenance in vivo. Telomerase-intrinsic and
extrinsic factors have been implicated in repeat addition
processivity [8–10], and our study suggests that inherited defects
that affect this unique property of the telomerase enzyme may
contribute to telomere length heterogeneity and to telomere-
mediated disease. Although individuals in the two kindreds we
describe carried two in cis variants in hTERT, our biochemical
studies suggest that hTERT 867M is likely the functionally
important mutation. As such, the hTERT 791I rare variant may
serve as a useful genetic marker and, along with the 867M, can
identify other families with shared ancestry to the families we
report herein. Single nucleotide titration studies have implicated
hTERT V867 to be important in telomerase function [28]. Studies
of the Tetrahymena thermophila TERT have also implicated the
orthologous residue adjacent to V867 in repeat addition
processivity [40]. These observations, along with our findings,
indicate that residues within motif C of the telomerase reverse
transcriptase domain are important determinants of telomere
repeat addition processivity. Several mechanisms of telomerase
haploinsufficiency have been previously reported for disease
causing mutations including loss of hTR stability, impaired
association of hTR with hTERT, and loss of catalytic function
[13,20,22,24,25]. In this study, the strong genetic evidence linking
the mutant TERT to a known telomere-mediated disease, and the
evidence of telomere shortening in vivo, indicate that the mutant
TERT affects telomere maintenance. Our in vitro biochemical
studies show that the mutant TERT is defective in repeat addition
processivity, pointing to this as the likely mechanism for the loss of
telomerase function and the consequent organ failure.
We report on an ancestral mutation in hTERT which
manifested independently in two pulmonary fibrosis families. To
our knowledge, hTERT 791I-867M is the most ancient telomerase
mutation, and it is likely that other kindreds with familial
pulmonary fibrosis and other features of telomere syndromes will
be subsequently found to share ancestry with these pedigrees. In
contrast to a family with a functionally null hTERT mutation
where genetic anticipation was striking and caused a two decade
earlier onset of disease across each generation [20], hTERT 791I-
first repeat addition as measured by the total intensity of the +1, +2, +3, and +4 nucleotide bands. Quantitation is based on 3 independent
experiments. * Indicates P-value ,0.01 and error bars indicate standard error of the mean. E. Quantitation of processivity across the first four repeats
(R1,R 2,R 3 and R4) is shown by the linear regression line.
doi:10.1371/journal.pgen.1001352.g003
Figure 4. Telomere length in mutation carriers in families 13 and 143 have short telomeres compared to age-matched controls.
Panel shows telomere length as measured in lymphocytes by flow-FISH compared to normal distribution of age-matched controls. Percentiles are
based on telomere length data from 400 controls. Squares refer to males and circles refer to females. Individuals refer to pedigree position in Figure 2.
Individual 13III.8 has short telomeres and was diagnosed with an overlap syndrome of emphysema and pulmonary fibrosis.
doi:10.1371/journal.pgen.1001352.g004
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we studied. This observation suggests that the extent of genetic
anticipation may correlate with the degree of telomerase loss-of-
function thus making genetic anticipation more difficult to detect
across consecutive generations in families that carry hypomorphic
mutations. Telomerase preferentially elongates the shortest
telomeres [41,42], and our functional studies which show intact
single repeat synthesis, point to the fact that the ancestral hTERT
791I-867M may have the capacity to add initial telomere tracts,
thus healing the shortest telomeres. However, with successive
telomere repeats, telomere addition is less efficient. Loss of
telomere repeat addition processivity may therefore be a
manifestation of more hypomorphic mutations, and therefore
adult-onset phenotypes, as the shortest telomeres may still be
elongated, albeit with shorter telomere tracts.
In this multi-generation study, although pulmonary fibrosis was
the most common manifestation in mutation carriers, several
individuals had extra-pulmonary manifestations of telomere-
mediated disease. One individual had avascular necrosis and
macrocytosis, two individuals reported history of cryptogenic liver
function abnormalities, and one patient had a history of AML
prior to the diagnosis of interstitial lung disease. Bone marrow
failure, avascular necrosis and cryptogenic liver cirrhosis are all
known complications of dyskeratosis congenita [17], and pulmo-
nary fibrosis families with mutant telomerase genes have been
known to have an increased incidence of aplastic anemia, a
common complication of dyskeratosis congenita [13]. AML, often
arising in the setting of myelodysplasia, has been recently reported
as a first manifestation of mutant telomerase genes [18,19], and it
is possible that families with pulmonary fibrosis due to telomerase
deficiency also have an increased incidence of AML. In 8
consecutive pulmonary fibrosis families with known hTR or
hTERT mutations, including the 2 we report herein, there was a
total of 3 first degree relatives of IPF probands who died with
AML at ages 25, 59, 68. Dyskeratosis congenita patients are
known to have an increased incidence of AML [16]. These
observations highlight the fact that a subset of families with
pulmonary fibrosis falls on the same spectrum as dyskeratosis
congenita and that the diagnosis of telomere syndrome in these
patients is relevant to their clinical work-up and surveillance.
Pulmonary fibrosis patients should be queried about a personal or
family history of AML, along with aplastic anemia, as part of the
screening history for a telomere syndrome.
In summary, an ancestral mutation within the reverse
transcriptase domain of telomerase manifests as familial pulmo-
nary fibrosis and causes defects in telomere repeat addition
processivity. Genetic factors that affect repeat addition processivity
may be important determinants of telomere length heterogeneity
across populations, and can contribute to understanding the
inherited basis of telomere-mediated disease.
Methods
Subjects and ethics statement
Subjects were recruited through the Vanderbilt Familial
Pulmonary Fibrosis Registry and gave written informed consent
[13]. The study was approved by the institutional review boards of
both Vanderbilt and Johns Hopkins Universities. The probands
from Families 13 and 143, and the majority of mutation carrier
and non-carrier relatives were clinically evaluated. Primary
medical records were used to document the diagnoses listed in
Table S1. We used the consensus classification to phenotype the
idiopathic interstitial lung disease [43].
Genotyping and telomere length measurement
Genomic DNA was extracted from peripheral blood using
standard methods. We sequenced hTERT [13] and confirmed
variants bidirectionally. Control DNA was obtained from Corriel
Figure 5. CAT scans from pulmonary fibrosis probands and non-carrier sibling with short telomeres. A,B show lower thoracic CAT scan
images from the probands in family 13 and 143. Both images show basilar honeycombing typical of idiopathic pulmonary fibrosis. C,D are apical and
lower thoracic CAT scan images respectively of sibling with short telomere who does not carry the mutant hTERT (Individual designated 13III.8 in
Figure 2 and Figure 3). This individual has apical changes consistent with centrilobular emphysema as well as lower thoracic ground glass changes
consistent with an interstitial process.
doi:10.1371/journal.pgen.1001352.g005
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similar to the families we studied. We used Merlin to calculate a
single point LOD score [44], under the assumption of autosomal
dominant inheritance and a 1/10,000 population frequency of
idiopathic interstitial lung disease. We determined allele size of
microsatellites D5S1981 (Forward-cctgtaccaatccatgc, Reverse-
gagccatgtgagtgtcc) and D5S2005 (Forward-cctcaggtgggttattgac,
Reverse-cccagggctttacgagt) using fluorescent labeled forward
primers obtained from Qiagen (Valencia, CA). PCR products
were analyzed on the ABI Genome Analyzer instrument (Applied
Biosystems). Pherograms were interpreted manually to determine
allele size. We amplified and genotyped mini-satellites/variable
number of tandem repeats within hTERT: 2–2 (intron 2) and 6–1
(intron 6) as published [45]. We determined the number of tandem
repeats using gel electrophoresis. Telomere length was measured
by flow-FISH on peripheral blood mononuclear cells [13].
Telomerase activity assay
TERT protein alignment was generated using CLUSTALW
followed by BoxShade analysis (v.3.21), and we used NP_937983
for the hTERT protein sequence. TERT sequences were obtained
from http://telomerase.asu.edu [46]. To test the activity and
processivity of the telomerase mutants, we expressed each of them
in vitro and quantified function using a direct telomerase activity
assay as previously described [10]. All telomerase variants were
reconstituted using the TNT (transcription and translation) Quick
Coupled rabbit reticulocyte lysate system (Promega) following
manufacturer’s instructions. Briefly, recombinant N-FLAG tagged
hTERT was expressed in 10 mL of TNT lysate with
35S labeled
methionine at 30uC for 60 minutes. To obtain active telomerase, in
vitro transcribed hTR pseudoknot (nt 32–195) and CR4-CR5 (nt
239–328) fragments were each added to a concentration of 8 mM
and incubated at 30uC for 30 minutes. To avoid variations in the
quality of telomerase reconstituted, the wildtype and variant
hTERT proteins were all expressed from the same batch of TNT
lysate and the reconstituted enzymes were assayed immediately
without freezing. To assay the activity and processivity of each
telomerase variant, a 10 ml reaction was carried out using 3 mlo fin
vitro reconstituted telomerase in the presence of 1x PE buffer
(50 mM Tris-HCl, pH 8.3, 50 mM KCl, 2 mM DTT, 3 mM
MgCl2, and 1 mM spermidine) and 2 pmol of 59-
32P end-labeled
(TTAGGG)3 telomere primer at 30uC for 1 h. Deoxynucleotides
(dATP, dTTP, and dGTP) were also included at concentrations of
either 1 mM or 10 mM, as indicated. Reactions were terminated
by phenol-chloroform extraction followed by ethanol precipitation
before being resolved on a 10% denaturing polyacrylamide gel. To
quantitate the first repeat product, we measured product intensity
at low exposure to clearly visualize the +1, +2, +3, +4 nucleotides
(as shown in Figure 3B), and normalized to the amount of
unpolymerized oligonucleotide loading control after subtracting
background. Telomerase processivity was calculated by measuring
the intensity of each repeat band, normalized to the intensity of the
first repeat, and plotted against the repeat number [9].
Supporting Information
Figure S1 Pulmonary fibrosis families 13 and 143 share a
common haplotype block flanking and within the hTERT locus. A.
Pedigrees of Families 13 and 143 with numbers below indicate
genotype at microsatellite D5S1981, variable number of tandem
repeats (VNTR) 6–1 in intron 6, and 2–2 in intron 2, as well as
microsatellite D5S2005, respectively from top to bottom. The
shared haplotype block is shown in bold and is shared by all
mutation carriers in families 13 and 143. * Refers to a mutation
carrier who shares the common haplotype block except at
D5S1981 where the allele is shorter by a single dinucleotide
repeat; this may be related to polymerase slippage or a
recombination event. The symbols are identified in the key, and
completely filled symbols indicate clinically affected individuals
who carry the double mutant TERT. B. Schema of hTERT locus
indicating the location of the genotyped micro- and mini-satellites
genotyped in this study. The vertical blocks within the hTERT
locus represent the 16 exons within the hTERT gene.
Found at: doi:10.1371/journal.pgen.1001352.s001 (1.51 MB EPS)
Table S1 Clinical Features of Probands and Mutation Carriers
(n=18).
Found at: doi:10.1371/journal.pgen.1001352.s002 (0.04 MB
DOC)
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